ReviewArchives of orthopaedic and trauma surgery2026
TGCT of the shoulder - a case series and literature review.
Review in Archives of orthopaedic and trauma surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTenosynovial giant cell tumor (TGCT), also known as pigmented villonodular synovitis (PVNS), involving the shoulder is extremely rare and can present with a challenging clinical course. Due to the complex anatomy of the shoulder, both diagnosis and treatment are demanding. This study aims to evaluate the diagnostic and therapeutic management of shoulder TGCT based on a case series and a review of the literature. MATERIALS AND
methodsBetween 2005 and 2021, four patients (2 females, 2 males) with shoulder TGCT (1 localized, 3 diffuse) underwent surgical treatment at our institution. The minimum follow-up was 39 months (range: 39–233 months). Functional outcomes were assessed using the Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH), the Oxford Shoulder Score (OSS), and the Short Form 36 Health Survey (SF-36). Additionally, a literature review of 65 studies comprising 108 patients was performed.
resultsTreatments consisted of arthroscopic and open resections, tendon repair, adjuvant radiosynoviorthesis, and radiotherapy, as appropriate. All patients were recurrence-free at the last follow-up, except for one with stable residual disease after radiotherapy. The mean interval from symptom onset to diagnosis was 23.6 ± 28.1 months. In the literature cohort, the mean patient age was 50.3 ± 19.7 years, with a nearly equal gender distribution. Diffuse TGCT was more common (66.1%) than nodular TGCT (33.8%). Treatment was primarily surgery, arthroscopic (53.2%) or open (42.9%), with adjuvant therapies applied in 9.3% of cases. After a mean follow-up of 37.6 ± 36.2 months in 67 cases, diffuse in 44.8%, nodular in 19.4% (no data regarding TGCT-type in 35.8%) the reported recurrence rate was 10.6% and 4.5% remained with residual disease.
conclusionsTGCT of the shoulder remains a rare and complex condition requiring individualized treatment strategies. Arthroscopic and open resections are the mainstays of therapy, while the role of adjuvant treatments should be carefully considered. Given the risk of recurrence, follow-up is essential. Further studies are needed to establish standardized treatment protocols and evaluate long-term outcomes. LEVEL OF EVIDENCE: Level IV (Case series with no comparison group).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.